Lixte Biotechnology Holdings, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 8/21/2017
Contact Info
  • 248 Route 25A
  • No. 2
  • East Setauket, NY 11733

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2017 10-Q
CIK 0001335105
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2006
Employees Not Available
Company Officers/Contacts
John S. Kovach, MD CEO, Principal Acct. Officer, Principal Fin. Officer
Eric J Forman Business Development
Company Directors
John S. Kovach, MD
Service Providers
Accounting/Auditing Firm
Weinberg & Company
1925 Century Park E.
Suite 1120
Los Angeles, CA, 90067
United States
Securities Counsel
TroyGould PC OTCQX Sponsor
1801 Century Park East
Suite 1600
Los Angeles, CA, 90067-2367
United States
Investor Relations Firm

Not Available
LIXT Security Details
Share Structure
Market Value1 $7,543,356 a/o Nov 17, 2017
Authorized Shares 100,000,000 a/o Nov 16, 2017
Outstanding Shares 58,025,814 a/o Nov 16, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC 6,120,848 a/o Nov 16, 2017
Float Not Available
Par Value 0.001
Transfer Agent(s) Verified by Transfer Agent
Shareholders of Record 84 a/o Mar 29, 2017
Short Selling Data
Short Interest 4,750 (0%)
Oct 13, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security